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which compares those at the extremes of susceptibility, revealsNephropathy in type 1 diabetes: A manifestation of insulin resis-
strong genetic associations and important interactions withtance and multiple genetic susceptibilities? Further evidence from
other risk factors not otherwise apparent.the Pittsburgh Epidemiology of Diabetes Complication Study.
Background. The pathogenesis of diabetic nephropathy re-
mains unclear, although previous reports implicate a wide
range of putative genetic and metabolic factors.
Overt diabetic nephropathy (ON) carries a high riskMethods. Incident and prevalent cases of overt nephropathy
of mortality in type 1 diabetes not only in its own right(ON), defined as an albumin excretion rate 200 g/min in
at least two of the three timed urines, from the Pittsburgh [1], but also as a risk factor for coronary artery disease
Epidemiology of Diabetes Complication Study (a prospective (CAD) [2]. The nature of this association with CAD is
epidemiologic study of an incident cohort of childhood onset intriguing, for despite the strong association seen in thetype 1 diabetic subjects) were studied.
initial reports from the Steno Clinic [2], recent observa-Results. Incidence analyses reveal differences in univariate
tions from both the United States [3, 4] and Europe [5, 6]baseline risk factors that predict ON within 5 years of measure-
ment [low-density lipoprotein (LDL) cholesterol, triglycerides, suggest the association is largely, if not totally, explained
white blood cell count, and hypertension] and those that predict by disturbed congenital vascular disease (CVD) risk fac-
in the long-term, that is, 6 to 10 years after baseline, hemoglobin
tors, notably blood pressure, lipids/lipoproteins, inflam-A1 (Hb A1). Estimated glucose disposal rate (calculated using
matory markers, and smoking. ON also appears to be aa formula derived from euglycemic-hyperinsulinemic clamp
studies), however, strongly (P 0.001) predicted ON through- stronger risk factor for CAD in men than in women with
out follow-up. Comparing individuals who were most suscepti- type 1 diabetes [3, 4].
ble to ON (those with an onset before 20 years duration of Whether these CVD risk factor mediators of the ON-type 1 diabetes and before the development of other advanced
CAD link arise largely from the well-known effect ofcomplications) with the least susceptible (late or no occurrence
renal disease on blood pressure and lipid metabolism,of ON despite the development of other advanced complica-
tions) revealed otherwise undetected genetic associations [that or whether they result from both ON and CAD sharing
is, apolipoprotein E (Apo E), angtiotensin-converting enzyme the same risk factors and/or genetic susceptibility, is dif-
insertion/deletion (ACE I/D), and lipoprotein lipase (LPL) ficult to determine. The demonstration that blood lipidsHindIII polymorphism) with odds ratios ranging from 2.9 to 7.1.
and blood pressure predict the incidence of microalbu-Conclusions. In type 1 diabetes insulin resistance is an un-
derlying risk state for ON, which may be accelerated by other minuria (MA) might support the latter hypothesis, for
disturbances (for example, hypertension and dyslipidemia). A MA is an early, sometimes reversible, stage of ON [7].
novel approach to classifying (that is, phenotyping) subjects, As MA is also associated with insulin resistance in the
non-type 1 diabetes population, the possibility arises that
insulin resistance, which is well-known to be related toKey words: diabetic nephropathy, levels, ApoE, ACE, predictors, lip-
ids, blood pressure. blood pressure elevation, disturbed lipid metabolism and
CAD [8] may underlie both ON and CAD and provideReceived for publication September 7, 2001
the link between them in type 1 diabetes.and in revised form March 25, 2002
Accepted for publication March 28, 2002 Several studies provide support for such an insulin resis-
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that 14 type 1 diabetic subjects with MA had significantly METHODS
lower glucose disposal during euglycemic-hyperinsulin- The Pittsburgh Epidemiology of Diabetes Complica-
emic clamp studies than did matched controls, even after tions (EDC) Study is a 10-year prospective study based
accounting for blood pressure and body mass index [9], on a well-defined cohort of adults with childhood-onset
while De Cosmo et al drew attention to the high preva- (17 years old) type 1 diabetes mellitus. There were 658
lence of CAD risk factors in parents of type 1 diabetes eligible subjects (325 women and 333 men) diagnosed
subjects with albuminuria [10]. These authors also re- between January 1, 1950, and May 30, 1980, who were
cently suggested that the rate of progression of ON may first seen at baseline (1986 to 1988). Two subpopulations
be predicted, in type 1 diabetes, by a variant of an inhibi- are studied in this report, the first of which compares
tor of insulin signaling PC1 glycoprotein [11]. A further incidence data derived from the 485 subjects without
set of data also suggest that the angiotensin-converting ON at baseline who have been followed up biennially
enzyme insertion/deletion (ACE I/D) polymorphism is thereafter. For these analyses, a prospective design was
associated with predisposition to both ON in type 1 dia- used in which baseline risk factors were compared to
betes [12] and to insulin resistance [13]. However, it is complication incidence over the ensuing 10 years. The
the D allele that predisposes to ON [12] and the I allele second subpopulation compares those designated highly
that is linked to insulin resistance [13]. Other studies “susceptible” to those designated highly “resistant” in
have cast doubt on the ACE I/D relationship to ON in terms of ON (vide infra). All cases, both incident and
type 1 diabetes [14]. Likewise, the evidence of whether prevalent, at baseline were available for this genetic anal-
ACE inhibition improves insulin sensitivity and glucose ysis. Susceptibility to ON was defined as developing ON
tolerance is also controversial with some reports showing within 20 years of type 1 diabetes onset and at least 4
no effect [15], while others suggest an improvement in years before developing either of the other two advanced
insulin sensitivity and glucose levels with use of ACE microvascular complications (proliferative retinopathy
inhibitors [16, 17]. or distal symmetrical polyneuropathy). Those resistant
Another potential genetic polymorphism related to to ON were defined as those with at least 20 years of
both CAD and insulin resistance is the apolipoprotein E type 1 diabetes duration who either did not develop ON,
(Apo E), wherein Apo E2 is associated with impaired or if they did, did not develop ON for at least 4 years
very-low-density lipoprotein (VLDL) remnant clearance after developing both of the other two complications. In
and type 3 dyslipidemia, and Apo E4 is linked to higher this way, we studied two groups of subjects who, although
cholesterol levels and CAD [18]. An interaction between susceptible to microvascular complications in general,
Apo E3/2 and insulin levels was also seen in the MRFIT were either specifically susceptible or resistant to ON.
nested-case control analyses in that insulin level was only Before attending each cycle of examinations, informa-
predictive of CAD in the subgroup of trial participants tion was collected by questionnaire concerning demo-
with Apo E3/2 phenotype [19]. Intriguingly, a similar graphic characteristics, medical history, and health care
Apo E/insulin interaction has been reported in Alzhei- behaviors as previously described. [28, 29] At each cycle,
mer’s disease, wherein those without Apo E4 have insu- both a standardized medical history and clinical exami-
lin resistance [20]. In addition, recent studies have also nation were performed by a trained internist to docu-
suggested associations between the Apo E polymorphism ment complications of diabetes.
and ON in diabetes [21–26]. Blood pressure was measured by a random-zero sphyg-
In order to further address these questions, we have momanometer according to a standardized protocol [Hy-
examined the 10-year follow-up data of the Pittsburgh pertension Detection and Follow-Up (HDFP)] [30] after
Epidemiology of Diabetes Complications Study cohort a 5-minute rest period. Blood pressure levels were ana-
of childhood-onset type 1 diabetes. In particular, we ad- lyzed, using the mean of the second and third readings.
dress (1) the predictive power (and time course of pre- Those on blood pressure medications or with a blood
diction) for ON of CVD risk factors, including insulin pressure140/90 mm Hg were classified as hypertensive.
resistance, using a surrogate marker [estimated glucose Fasting blood samples were assayed for lipids, lipopro-
disposal rate (eGDR)], which has been previously vali- teins, and hemoglobin (Hb A1). High-density lipoprotein
dated by euglycemia-hyperinsulemic clamp studies [27] (HDL) cholesterol was determined by a heparin and
for developing ON; (2) whether specific genetic polymor- manganese procedure, a modification [31] of the Lipid
phisms [ACE I/D, Apo E and lipoprotein lipase (LPL) Research Clinics method [32]. Cholesterol was measured
HindIII], which have been previously linked to insulin enzymatically [33], as were triglycerides [34]. Low-den-
resistance, ON, and/or lipid metabolism, distinguish those sity lipoprotein (LDL) cholesterol levels were calculated
with high and low susceptibility for ON; and (3) whether from measurements of the levels of total cholesterol,
the genetic polymorphisms relate to ON risk via insulin triglycerides, and HDL cholesterol [35].
Stable glycosylated Hb A1 was originally measured inresistance and/or other measured risk factors.
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Table 1. Baseline characteristics of type 1 diabetes subjects by incidence overt nephropathy (ON) status: Pittsburgh Epidemiology
of Diabetes Complications Study 10-year follow-up, meanSD or % (N )
ON ON P value P value
No ON 1 to 5 years after baseline 6 to 10 years after baseline No vs. ON No vs. ON
(N  429) (N  27) (N  29) 0 to 5 years 6 to 10 years
Age years 25.997.86 30.727.91 24.946.74 0.003 0.482
Duration years 18.017.29 21.007.53 15.177.00 0.040 0.042
eGDR mg/Kg/min 8.371.48 7.071.67 7.351.77 0.000 0.001
Waist hip ratio 0.810.07 0.850.07 0.820.08 0.004 0.715
Hb A1 % 10.221.72 10.832.31 11.792.21 0.083 0.000
HDL cholesterol mg/dL 54.8211.83 51.5013.46 55.0411.01 0.161 0.924
LDL cholesterol mg/dL 107.3128.01 126.5932.81 116.1535.31 0.001 0.133
Triglycerides mg/dL 93.2274.60 128.2376.46 105.3655.73 0.001 0.134
N-HDL cholesterol mg/dL 125.3433.54 150.2437.64 135.2140.85 0.000 0.138
White blood cell count103/mm3 6.231.71 7.792.14 6.221.60 0.000 0.998
Systolic blood pressure mm Hg 109.1110.99 114.1112.68 109.1016.00 0.024 0.997
Diastolic blood pressure mm Hg 70.038.84 72.4810.80 70.769.63 0.169 0.670
Sex % female 49 (N  210) 56 (N  15) 45 (N  13) 0.506 0.667
Hypertension % 5 (N  21) 19 (N  5) 7 (N  2) 0.012 0.642
Ever smoked % 32 (N  130) 48 (N  13) 39 (N  11) 0.094 0.45
Abbreviations are: eGDR, estimated glucose disposal rate; Hb A1, hemoglobin A; HDL, high-density lipoprotein; LDH, low-density lipoprotein
Table 2. Characteristics of EDC study subpopulation designatedsaline-incubated samples by microcolumn cation ex-
nephropathy susceptible or resistant,a meanSD or % (N )
change chromatography (Isolab, Akron, Ohio, USA).
Susceptible Resistant P valueOn October 26, 1987, the method was changed to high-
Number 23 61 —performance liquid chromatography (HPLC) (Diamat,
Age years 23.44.4 32.56.06 0.000Bio-Rad Laboratories, Hercules, CA, USA). The two
Duration years 13.53.2 24.56.09 0.000
methods were highly correlated (r  0.95; Diamat Hb Hb A % 11.11.90 10.61.83 0.374
EGDR mg/kg/min 7.91.65 7.51.83 0.328A1  0.18  1.00 Isolab Hb A1). The difference between
Waist hip ratio 0.810.08 0.840.07 0.164the means of the two methods was 0.158% (normal
HDL cholesterol mg/dL 59.915.7 52.810.9 0.025
range, 4.9% to 7.3% Hb A1). LDL cholesterol mg/dL 121.950.7 115.730.2 0.525
Log triglycerides mg/dL 4.540.49 4.410.52 0.311Nephropathy status was determined based on consis-
Non-HDL cholesterol mg/dL 142.750.8 134.736.3 0.439tent results from at least two of three timed urine collec-
White blood cell 103/mm3 6.681.49 6.521.95 0.741
tions (24-hour, overnight, random timed post-clinic) and Systolic blood pressure mm Hg 114.99.93 112.015.1 0.412
Diastolic blood pressure mm Hg 74.510.5 72.810.8 0.540urine albumin excretion rates (AER). Urinary albumin
Gender % male 33.3 (7) 42.5 (28) 0.343was determined immunonephelometrically [36]. ON was
Hypertension % 4.8 (1) 16.1 (10) 0.275
defined as an AER 200 g/min or end-stage renal dis- Ever smoked % 15.0 (3) 52.5 (32) 0.003
ease (ESRD; renal dialysis or transplant). eGDR was Abbreviations are: Hb A, hemoglobin A; eGDR, estimated glucose disposal
rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.calculated using the equation: eGDR 24.31- 12.22 (waist
a See text for definitionhip ratio) – 3.29 [hypertension status (140/90 mm Hg
or on medications)] – 0.57 (Hb A1). This equation was
derived from a substudy of 24 EDC participants (12 men
determined by the methods of Hixson and Vernier [39],and 12 women drawn from low, middle and high age-
Tiret et al [40], and Ahn et al [41], respectively. Geno-specific tertiles of insulin resistance risk factors in order
types were assigned by direct comparison to controls ofto represent the spectrum of insulin resistance) who un-
known genotype.derwent euglycemic-hyperinsulinemic clamp studies
[27]. This subgroup was comparable to those studied in Statistical analyses
this report except for a lower HDL cholesterol (P  Continuous variables were compared across groups
0.02). Proliferative retinopathy (PR) was determined by by Student t test with triglycerides being log transformed
stereoscopic fundus photography and grades 60 on the prior to testing. Categorical variables were compared
modified Airlie House System or laser therapy for PR. across groups by chi-square tests. These analyses were
DSP was based on a clinical neurological evaluation, per- based on risk factors (predictors) assessed at baseline
formed by a trained internist, consistent with that used (Table 1).
for the DCCT [37]. In addition, a genetic analysis was performed on a
Peripheral lymphocyte DNA was isolated by the salt- highly select subgroup of subjects chosen to maximize the
ing-out procedure of Miller, Dykes and Polesky [38] and extremes of susceptibility to nephropathy as described
earlier (Tables 2 and 3). All subjects (including thoseApo E, ACE I/D, and LPL HindIII genotypes were
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Table 3. Odds ratio for overt nephropathy (ON) in associationwith ON at baseline) were considered for inclusion in this
with susceptible and resistant subgroupsa: Pittsburgh
analysis. The association of three genetic polymorphisms Epidemiology of Diabetes Complications Study
cohort status as of 10-year follow-up datawith susceptibility status was examined using chi-square
testing and calculation of odd ratios and confidence inter- 95% Confidence
vals. A final multivariate Cox proportional hazards re- Odds ratio interval
gression analysis was conducted adding the genetic mark- ACE D/D vs. I/I or I/D 2.94 1.09–8.33
Apo E 2/2 or 2/3 vs. rest 5.09 1.32–19.60ers identified in the genetic subgroup to the original
Apo E 4/3 or 4/4 vs. rest 3.31 1.11–9.88baseline predictors of 10-year incidence (Table 4).
Apo E non 3/3 vs. 3/3 7.12 2.54–20.36
LPL HindIII /, / vs. / 3.56 1.25–0.12
Abbreviations are: ACE D/D, angiotensin-converting enzyme deletion/dele-RESULTS
tion; ACE I/I, angiotensin-converting enzyme insertion/insertion; ACE I/D, an-
giotensin-converting enzyme insertion/deletion; Apo E, apolipoprotein E; LPL,Table 1 contrasts the baseline (1986 to 1988) character-
lipoprotein.istics of the 56 subjects who went on to develop ON a See text for definition
during either the first 5 years, or 6 to 10 years after base-
line risk factor measurement, with the 429 who did not.
Those developing ON within 5 years of baseline were
In order to determine if the three candidate genesolder and had a longer duration of type 1 diabetes than
examined, ACE I/D polymorphism, Apo E polymor-those who remained ON free, while those developing
phism (E2, E3, and E4) and LPL HindIII (/), relatedON later (6 to 10 years past baseline) were similarly aged
to ON susceptibility, these polymorphisms were exam-but had a shorter duration than the ON-free group. In
ined in the two subgroups defined earlier, ON susceptiblethe early-onset group, strong relationships (P  0.001)
(N  23) and ON resistant (N  61). Table 2 shows thewere seen between the incidence of ON and eGDR,
baseline risk factors for these two subgroups while Tablewaist hip ratio, white blood cells, total and LDL choles-
3 shows odds ratios and 95% confidence intervals.terol, and triglycerides (or non-HDL cholesterol). How-
As shown in Table 3, homozygosity for the ACE Dever, only eGDR along with Hb A1 (P  0.001) strongly
allele is associated with susceptibility to ON, while thepredicted ON in the “later” ON incident group. Hb A1
presence of either an Apo E2 or an Apo E4 allele waswas weakly related to “early” ON (P  0.08). Like the
related to susceptibility status. In contrast, the absencelipid factors, blood pressure (either systolic or hyperten-
of a LPL HindIII () allele was associated with suscepti-sion) was only related to ON early in the onset group.
bility.Furthermore, blood pressure appeared to be a weaker
In order to determine if these genetic polymorphismspredictor than the lipid measures.
were related to nephropathy independent of the specificIn a Cox regression model to which all univariate pre-
risk factors identified earlier, three multiple logistic re-dictors (P 0.05) in Table 1 were available, only eGDR
gression analyses were run wherein each genetic marker(P  0.0001) and white blood cell count (P  0.01) – 2
was entered followed by the other risk factors selectedlog likelihood  481.9 were shown to be independent
by forward stepwise regression. Because of the smallpredictors of ON (both early and late combined). As
numbers, Apo E was entered as non-3/3 versus the rest,eGDR is a function of waist hip ratio, Hb A1 and hyper-
ACE as D/D versus the rest and LPL HindIII as /tension, the model was repeated without eGDR being
versus the rest.available. As anticipated, Hb A1 (P 0.000), white blood
In the Apo E model, age (P  0.002), eGDR (P cell count (P  0.001), and systolic blood pressure (P 
0.003), and systolic blood pressure (P  0.015) were all0.002) were independent predictors with –2 log likeli-
significant predictors of ON. However, the OR for non-hood as 486.1. These two models had similar –2 log
Apo E 3/3 doubled to 14.92 (compared to Table 2),likelihood and fit equally well when the deviance residu-
although its significance declined (P  0.015). In theals were examined. Comparison of these two models
ACE model, age, eGDR, and systolic blood pressurewere then made on the basis of Akaike’s Information
progressively reduced both the odds ratio and P valueCriterion (AIC  2 log likelihood  2  number of
for D/D to 1.71 (P 0.564). For the LPL HindIII model,parameters in the model) based on which the eGDR
age, eGDR, and systolic blood pressure entered themodel is preferable to the model with Hb A1 and systolic
model while the odds ratio for non / increased toblood pressure. Although the number of incident cases
8.77 (although again the P value weakened from 0.02 tois small when stratified by onset (within 5 years or from
0.06). Modeling after eliminating either eGDR or sys-6 to 10 years), Cox models performed with and without
tolic blood presssure (as they are related) did not altereGDR being available suggest that eGDR (P  0.001)
the LPL findings (nonsignificant as above), although theand white blood cell count (P  0.001) are early pre-
odds ratio for developing ON was higher when eGDRdictors and Hb A1c (P  0.001) is the main long-term
predictor. was available.
Orchard et al: Nephropathy risk in type 1 diabetes 967
Table 4. Multivariate predictors (include genetic polymorphisms) of the 10-year incidence of overt nephropathy (ON)
in the Pittsburgh Epidemiology of Diabetes Complications Study
Model 1 Model 2 Model 3 Model 4
OR P value OR P value OR P value OR P value
Full 10-year incidence
Apo E (not 3/3) 0.57 0.08 0.50 0.03 0.55 0.07
ACE D/D 0.83 0.56 1.06 0.86 1.26 0.52
LPL HindIII (not /) 0.97 0.93 0.90 0.76 0.86 0.64 N/A
eGDR 0.62 0.001 0.63 0.001
White blood cells 1.21 0.02
0 to 4.99 year incidence
Apo E (not 3/3) 0.69 0.38 0.74 0.48 0.63 0.29 0.66 0.35
ACE D/D 0.56 0.18 0.67 0.36 0.86 0.74 0.73 0.50
LPL HindIII (not /) 1.56 0.30 1.59 0.28 1.45 0.39 1.53 0.33
White blood cells 1.49 0.001 1.42 0.001 1.39 0.002
eGDR 0.68 0.001 0.69 0.002
Duration 1.06 0.04
5 to 10 year post baseline incidence
Apo E (not 3/3) 0.44 0.08 0.31 0.02 0.30 0.01
ACE D/D 1.23 0.63 1.58 0.42 1.79 0.31
LPL HindIII (not /) 0.56 0.24 0.36 0.06 0.39 0.08 N/A
GHb 1.91 0.001 1.58 0.003
eGDR 0.70 0.04
Baseline predictors available for modeling: Apolipoprotein E (Apo E; not 3/3: Yes/No), angiotensin-converting enzyme insertion/deletion (ACE I/D), low-density
lipoprotein (LDL) HindIII, duration of type 1 diabetes, estimated glucose disposal rate (eGDR), waist hip ratio, body mass index (BMI), GHb, HDL cholesterol,
LDL cholesterol, triglycerides, non-HDL cholesterol, systolic blood pressure, and diastolic blood pressure.
Finally, having identified these genetic associations tors. In addition, this study also presents a novel way to
explore genetic susceptibility and reveals, in a specificwith ON using the select susceptibility subgroups, we
repeated the original incidence analyses after first enter- subgroup, enhanced risk associated with Apo E, ACE
I/D, and LPL HindIII polymorphisms and importanting the three genetic markers into the Cox proportional
hazard model (Table 4). None of the three polymor- interactions and interdependencies with other risk fac-
tors, as shown in Table 4.phisms (ACE I/D, LPL HindIII, or Apo E) were signifi-
The concept that insulin resistance is associated withcant in the final model with all 56 ON incident cases as
ON has been proposed before. Yip et al [13] exploredthe outcome variable. Similarly, these polymorphisms
insulin resistance as an underlying factor in type 1 diabe-did not contribute to the model for early onset ON (0
tes and found a reduced glucose disposal in a small groupto 5 years post baseline). However, for the later onset
with MA, while De Cosmo has potentially linked such agroup (6 to 10 years post baseline), Apo E (P  0.01)
susceptibility to a PC1 insulin signaling glycoprotein [11].significantly contributed along with eGDR and GHb,
However, ours is the first study to use eGDR (an equationand the LPL HindIII showed a borderline relationship
derived from euglycemic-hyperinsulinemic clamp studies)(P 0.08) in the opposite direction (non/was protec-
in a large cohort of type 1 diabetes. Nonetheless, it cantive). It is also seen that the strength of the Apo E (not
be argued that, as this equation to estimate GDR is based3/3) and LPL HindIII associations increases with the
on three risk factors (waist hip ratio, Hb A1, and hyper-addition of GHb and eGDR to the model.
tension), all we are doing is “statistical manipulation.”
While eGDR is undoubtedly a statistical calculation, this
DISCUSSION computation is strongly related to measured GDR (r 
These results provide a unique opportunity to assess 0.76) [27] and those scoring high on eGDR clearly have
both the genetic and insulin resistance contributions to better insulin sensitivity and reduced ON risk. Further-
ON in a well-characterized childhood-cohort type 1 diabe- more, the physiological basis of insulin sensitivity being
tes representative epidemiologically of a population-based related to waist hip ratio, hypertension, and glucose intol-
registry [42]. The major findings are the clear demonstra- erance is well founded and described by many authorities
tion that eGDR (insulin sensitivity) is the predominant [43–45]. On balance, and in the context of prior type 1
predictor of ON along with white blood cell count and diabetes studies, it seems reasonable to conclude that the
that blood pressure (beyond any association with eGDR) strong predictive power of eGDR truly reflects insulin
and lipids appear to only predict in the short term. This resistance as a pathophysiological risk factor and not just
suggests that the latter mainly act as late-stage accelera- a statistical anomaly. As eGDR is a predisposing factor
for two well-established ON predictors, namely hyper-tors or precipitators rather than underlying etiologic fac-
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tension and glycemia [46, 47], as well as being a strong tion out of the triopathy of PR, distal symmetric polyneu-
ropathy (DSP), and ON. In this study, we contrastedcorrelate of excess central adiposity (represented in our
analyses by waist hip ratio), it could be a very plausible the ON-susceptibile and ON-resistant subjects with the
susceptible comprising those who develop ON early (be-underlying aetiologic factor [48].
The role of glycemia, per se, is particularly intriguing. fore 20 years of duration) and at least 4 years before PR
or DSP, and the resistant as those who have gone 20It is well established as a major predictor for MA [47, 49],
which is an obligatory precursor of ON although ON is years of type 1 diabetes without ON despite having PR
and DSP. The genes we chose to examine were thosefar from an inevitable consequence of MA as recently
reviewed by Caramori, Fioretto, and Mauer [50]. The previously related to ON (ACE I/D and Apo E) or its
risk factors (promoters), blood pressure (ACE I/D), lipo-DCCT clearly showed the benefit of reducing glycemia in
delaying (or preventing) this early stage [47]. However, protein metabolism (ApoE and LPL HindIII), and insu-
lin resistance (ACE I/D and ApoE). We anticipated thatglycemia appears to be a weaker predictor of the further
progression of MA to ON even in the DCCT [51]. War- the polymorphisms associated with the putative risk fac-
tor would exacerbate the predictive power of that factor.ram et al have recently provided further insight on this
progression with 4-year follow-up data from the Joslin Generally, however, the reverse is true, suggesting that
these genetic factors are “hidden” due to the overridingClinic that showed that progression of MA to frank albu-
minuria rose steeply between an Hb A1 of 7.5 to 8.0% influence of glycemia and other phenotypic risk factors,
lipoprotein levels and blood pressure, to which theseand then flattened out [52]. In an earlier 1996 report, we
presented data concerning the stepwise progression of genes contribute in a multifactorial way.
In the case of ACE I/D, while the D/D state has beennormal albuminuria to MA and then onto ON [53]. Hb A1
was a predictor of MA going on to ON in men (10.8% inconsistently related to ON risk [14, 55], it is the I allele
that is related to insulin resistance [13]. Our demonstra-versus 10.1%, P  0.02) but not women (10.7% versus
10.8%, P  NS). Although these data were not included tion that D/D is only predictive in the susceptible/resis-
tant subgroup (OR  2.9, P  0.04) but loses strengthin a recent review, Caramori, Fioretto, and Mauer [50]
also examined the progression of MA to ON and con- and significance (OR  1.71, P  0.564) in the full Cox
model when age, eGDR and systolic blood pressure arecluded that rates were generally lower than originally pro-
jected and that there was a need for new markers to present, is consistent with it having a small role, largely
accounted for by blood pressure and independent of theidentify those at true risk. The current analysis thus at-
tempts to provide further insight into these issues by ex- association between the I allele and insulin resistance.
Interestingly, at the step that eGDR entered the Coxploring the temporal relationship between glycemia, blood
pressure, and dyslipidemia and subsequent ON. The cur- model, the odds ratio for D/D increased slightly, perhaps
suggesting that its influence is counteracted (masked) byrent data are consistent with glycemia being an underly-
ing consistent risk factor leading to both MA in the short the ACE inhibitors/insulin resistance association. These
results, therefore, shed light on possible explanations forterm [49] and to ON over the long-term (Table 1) with
dyslipidemia (both increased LDL cholesterol and tri- the inconsistency in the literature concerning ACE D/D
and the development of ON.glycerides) being a short-term predictor or promoter (only
becomes relevant later in the process and acts mainly to The association between either Apo E2 or Apo E4 and
increased ON risk (OR  7.2, P  0.001) is particularlyaccelerate the process). Blood pressure, per se, would
seem (Table 1) to follow a similar pattern although it intriguing. In our analysis of the susceptible/resistant
subgroup, this risk is independent of (and possibly en-appears to be a weaker predictor/promoter. On this ba-
sis, the general underlying pathology is related to hyper- hanced by) controlling for age, eGDR and systolic blood
pressure (OR  14.9, P  0.01). These results suggest,glycemia and its tissue consequences and this effect will
be seen over a prolonged follow-up period. It thus fol- therefore, that either the disturbed lipoprotein patterns
associated with Apo E (increased LDL cholesterol withlows, as we have previously argued, that most type 1
diabetic subjects will develop most microvascular com- Apo E4 and triglycerides/non-HDL cholesterol with Apo
E2), or other non-measured factors associated with theseplications given sufficient glycemic exposure [49, 54]. If
that is the case, then in the majority of cases, genetic polymorphisms/lipoproteins, increases risk of ON. Some
support for this conclusion is drawn from Table 1, whichsusceptibility would have only a minor role to play given
an overriding influence of glycemia and duration. With shows LDL cholesterol and triglycerides (or both as non-
HDL cholesterol) as being predictives. Clearly, however,that in mind, we decided to explore our database for
the exceptional cases that would most likely represent the in our susceptible/resistant subgroup, non-Apo E 3/3
appeared to provide better prediction of ON risk thangenetic susceptibilities, which are not contributing to the
majority of glycemic related cases. This “complication” the lipoproteins, which may, therefore, only partially
represent the metabolic disturbance (and ON risk) asso-profiling was designed to identify subjects with specific
susceptibility (or resistance) to one particular complica- ciated with non-Apo E 3/3 genotypes. The literature on
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